Image for Pipeline Overview Page

Pipeline Overview

Delivering on the RNA Revolution

We are advancing and expanding our innovative AOC pipeline to offer treatment options for patients and their families across a wide range of therapeutic areas. We have three AOC programs for three distinct rare diseases in clinical development from our muscle disease franchise: myotonic dystrophy type 1 (DM1), facioscapulohumeral muscular dystrophy (FSHD), and Duchenne Muscular Dystrophy (DMD). Our pipeline also includes advancing AOCs to address additional DMD and rare neuromuscular programs. 

  Back to top
2026 Pipeline

Study drug(s) and AOC™ technology are investigational. Efficacy and safety have not been established and there is no guarantee that the therapies will become commercially available for the use(s) under investigation.